Deal supported by Xplico
Bavarian Nordic Enters Licensing and Collaboration Agreement with Janssen for MVA-BN® in the Development of a Therapeutic HPV Vaccine.
Bavarian Nordic Enters Licensing and Collaboration Agreement with Janssen for MVA-BN® in the Development of a Therapeutic HPV Vaccine.
LEO Pharma to acquire global dermatology portfolio from Astellas.
ObsEva and Kissei Pharmaceutical Announce Global Agreement to Develop and Commercialize KLH-2109 for the Treatment of Endometriosis.
Sanofi and Lexicon Pharmaceuticals to Collaborate on Sotagliflozin, an Investigational New Oral Medicine for People with Diabetes.
Nuevolution Announces Drug Discovery Collaboration with Johnson & Johnson Innovation.
PharmaMar announces license agreement with Specialised Therapeutics Australia Pty for
APLIDIN® (plitidepsin) in oncology.
Inovio Pharmaceuticals enters into Strategic Cancer Vaccine Collaboration and License Agreement with MedImmune
PharmaMar announces license agreement with TTY Biopharm for APLIDIN® (plitidepsin) in hematological cancers
LEO Pharma Enters Supply and Distribution Agreement with NeoPharm on Non-Prescription Skin Care Solutions
arGEN-X and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditions
HRA Pharma Closes Investment in Embera NeuroTherapeutics to Advance Development of Novel Therapies for Addiction
4SC Signs Licensing and Development Agreement with Menarini for Resminostat in Asia-Pacific Excluding Japan
Medivir and Cancer Research Technology collaborate to develop new class of cancer drugs
Immunocore and MedImmune enter immunotherapy agreement to develop novel cancer therapies
Bristol-Myers Squibb and uniQure Enter into Exclusive Strategic Collaboration to Develop Gene Therapies for Cardiovascular Diseases
Bristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for PROSTVAC®, a Prostate-Specific Antigen-Targeting Cancer Immunotherapy
Curis and Aurigene Announce Collaboration, License and Option Agreement to Discover, Develop and Commercialize Small Molecule Antagonists for Immuno-Oncology and Precision Oncology Targets